Amarantus BioScience Holdings, Inc. (OTCBB: AMBS) is a biotech company discovering and developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, including protein misfolding, cell cycle dysregulation, neurodegeneration and apoptosis (Programmed Cell Death). The company is focused on developing certain small molecules, biologics and biomarkers surrounding the intellectual property and proprietary technologies it owns and to which it has licenses to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Retinitis Pigmentosa and other human diseases. For more information, visit the company’s website at www.amarantus.com